Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2007

View Archived Issues

Novel antiinfective agents disclosed in recent patent literature

Snapshots from the 2007 Gastrointestinal Cancers Symposium: Part I

CF-101 studied for dry eye syndrome in new phase II study

ND-0601 transdermal levodopa patch completes pilot study

DiaKine Therapeutics and AdPharma to develop pipeline for reversing diabetes

Methylphenidate to commence clinical trial for the treatment of cancer-related fatigue

Johnson & Johnson completes acquisition of Conor Medsystems

Starpharma continues studies of microbicide VivaGel

DelSite licenses technology to AriaVax for HIV vaccine

Progress reported in Riquent phase III study

KI-23057 shows preclinical activity against different types of cancer

Neurochem completes North American phase III study of tramiprosate

Generex begins phase II trial for AE-37 in breast cancer

Shionogi and Lilly to codevelop and comarket duloxetine in Japan

Losartan normalizes muscle architecture, repair and function in mouse models of myopathic disorders

Blockade of the orexin OX1/OX2 receptors with ACT-078573 promotes sleep in rats, dogs and humans

Mitsubishi Pharma to merge with Tanabe Seiyaku

Schering-Plough licenses AN-2690 for onychomycosis

Bioral amphotericin set to begin clinical testing

Pivotal Acapodene trials recommended to continue

KI-26894: a novel inhibitor of TGF-beta receptor inhibits tumor growth and prolongs survival in mice

RTP-801i for wet AMD begins phase I study

Erbitux filed in Japan for metastatic colorectal cancer

Recent patents report novel therapeutic agents for metabolic diseases

Wyeth and Nautilus to develop recombinant Factor IX proteins for hemophilia B

Genta completes response to EMEA for Genasense MAA in advanced melanoma

Virginia Commonwealth University and Nicogen jointly divulge novel antismoking agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...